BACKGROUND: Microbiota is known to influence response to anticancer immunotherapy. We examined whether antibiotic usage could impact nivolumab efficacy in patients treated for non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Seventy-four patients with NSCLC were included in this retrospective study. They received nivolumab between 2015 and 2016 (3 mg/kg i.v. q2w). The association between RECIST response and antibiotic usage was determined using Chi-square and Cox proportional hazard model. RESULTS: A total of 17, 21 and 36 patients experienced response, stable disease and progression disease under nivolumab. Only 15 (20.3%) patients were exposed to antibiotic medication in the 3 months before the first nivolumab injection or during treatment. We found a similar response rate for the two populations, without impact of antibiotic exposure (Chi-square test p=0.75). Moreover, we observed no impact of antibiotic medication on progression-free survival under nivolumab (log-rank test, p=0.72). CONCLUSION: Microbiota modification induced by antibiotics does not appear to affect the efficacy of nivolumab in patients with NSCLC. Copyright
BACKGROUND: Microbiota is known to influence response to anticancer immunotherapy. We examined whether antibiotic usage could impact nivolumab efficacy in patients treated for non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Seventy-four patients with NSCLC were included in this retrospective study. They received nivolumab between 2015 and 2016 (3 mg/kg i.v. q2w). The association between RECIST response and antibiotic usage was determined using Chi-square and Cox proportional hazard model. RESULTS: A total of 17, 21 and 36 patients experienced response, stable disease and progression disease under nivolumab. Only 15 (20.3%) patients were exposed to antibiotic medication in the 3 months before the first nivolumab injection or during treatment. We found a similar response rate for the two populations, without impact of antibiotic exposure (Chi-square test p=0.75). Moreover, we observed no impact of antibiotic medication on progression-free survival under nivolumab (log-rank test, p=0.72). CONCLUSION: Microbiota modification induced by antibiotics does not appear to affect the efficacy of nivolumab in patients with NSCLC. Copyright
Authors: Mara Cruellas; Alfonso Yubero; María Zapata; Eva M Galvez; Marta Gascón; Dolores Isla; Rodrigo Lastra; Luis Martínez-Lostao; Maitane Ocariz; Julián Pardo; Ariel Ramírez; Andrea Sesma; Irene Torres-Ramón; José Ramón Paño Journal: Infect Immun Date: 2021-08-16 Impact factor: 3.441
Authors: I Puzanov; A Diab; K Abdallah; C O Bingham; C Brogdon; R Dadu; L Hamad; S Kim; M E Lacouture; N R LeBoeuf; D Lenihan; C Onofrei; V Shannon; R Sharma; A W Silk; D Skondra; M E Suarez-Almazor; Y Wang; K Wiley; H L Kaufman; M S Ernstoff Journal: J Immunother Cancer Date: 2017-11-21 Impact factor: 13.751